Kenneth Nephew

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller D, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res. 2014;20:6504-16 pubmed publisher
    ..Specifically, SGI-110 in combination with conventional and/or targeted therapeutics warrants further development in this setting. ..
  2. Wang Y, Cárdenas H, Fang F, Condello S, Taverna P, Segar M, et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014;74:4922-36 pubmed publisher
    ..Furthermore, the results suggest that SGI-110 might be administered in combination with platinum to prevent the development of recurrent and chemoresistant ovarian cancer. ..
  3. Fang F, Cárdenas H, Huang H, Jiang G, Perkins S, Zhang C, et al. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs. Cancer Res. 2018;78:631-644 pubmed publisher
    ..b>Significance: Epigenomic targeting may improve therapeutic outcomes in platinum-resistant and recurrent ovarian cancer in part by effects on DNA repair and antitumor immune responses. Cancer Res; 78(3); 631-44. ©2017 AACR. ..
  4. Pulliam N, Tang J, Wang W, Fang F, Sood R, O Hagan H, et al. Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells. Cancers (Basel). 2019;11: pubmed publisher
    ..These results correlate ERα PARylation with tamoxifen resistance and indicate a novel mechanism-based approach to overcome tamoxifen resistance in ER+ breast cancer. ..
  5. Stack M, Nephew K, Burdette J, K Mitra A. The Tumor Microenvironment of High Grade Serous Ovarian Cancer. Cancers (Basel). 2018;11: pubmed publisher
    ..The Special Issue on high grade serous ovarian cancer (HGSOC) and the contribution of the tumor micro-environment (TME) consisted of reviews contributed by leaders in the ovarian cancer (OC) field. [...]. ..
  6. Klymenko Y, Nephew K. Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled. Cancers (Basel). 2018;10: pubmed publisher
    ..Promising research directions and potential therapeutic strategies that may encompass epigenetic tailoring as a component of complex EOC treatment are discussed. ..
  7. Tang J, Pulliam N, Ozes A, Buechlein A, Ding N, Keer H, et al. Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion. Mol Cancer Res. 2018;16:1226-1240 pubmed publisher
    ..b>Implications: Epigenetic targeting of tumor microenvironment can affect metastatic behavior of ovarian cancer cells. Mol Cancer Res; 16(8); 1226-40. ©2018 AACR. ..
  8. Özeş A, Pulliam N, Ertosun M, Yilmaz O, Tang J, Çopuroğlu E, et al. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. Oncogene. 2018;37:3589-3600 pubmed publisher
    ..These findings demonstrate that PKA-mediated T372 phosphorylation reduces oncogenic EZH2 activity and reveal a novel role for pT372 in regulating EZH2 in OC and possibly other cancers. ..
  9. Pulliam N, Fang F, Özeş A, Tang J, Adewuyi A, Keer H, et al. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Clin Cancer Res. 2018;24:3163-3175 pubmed publisher
    ..i>Clin Cancer Res; 24(13); 3163-75. ©2018 AACR. ..

More Information

Publications14

  1. Conger A, Martin E, Yan T, Rhodes L, Hoang V, La J, et al. Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. Noncoding RNA. 2016;2: pubmed publisher
    ..Together with our clinical findings on AGO2 expression and the luminal B subtype, we suggest that AGO2 is a regulator of altered ERα signaling in breast tumors. ..
  2. request reprint
    Nephew K, Osborne E, Lubet R, Grubbs C, Khan S. Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat. Proc Soc Exp Biol Med. 2000;223:288-94 pubmed
    ..The data may have implications for risk assessment of these agents prior to administration to healthy, cancer-free women. ..
  3. request reprint
    Miller D, Yan P, Fang F, Buechlein A, Kroll K, Frankhouser D, et al. Complete Transcriptome RNA-Seq. Methods Mol Biol. 2017;1513:141-162 pubmed
    ..We employ the Illumina sequencing platform, but this method is described in sufficient detail to adapt to other platforms. ..
  4. Özeş A, Wang Y, Zong X, Fang F, Pilrose J, Nephew K. Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep. 2017;7:894 pubmed publisher
    ..This first report on pHLIP-PNA lncRNA targeting solid tumors in vivo suggests a novel cancer therapeutic approach. ..
  5. request reprint
    Nephew K, Ray S, Hlaing M, Ahluwalia A, Wu S, Long X, et al. Expression of estrogen receptor coactivators in the rat uterus. Biol Reprod. 2000;63:361-7 pubmed
    ..Furthermore, we speculate that higher constitutive levels of coactivator expression in glandular and luminal epithelial cells may be associated with increased hormonal responsiveness by these uterine compartments. ..